Provided herein are peptides that mimic the activity of endogenous catalase. In particular, catalase mimetic peptides and methods of use thereof for the treatment or prevention of diseases such as cancer are provided.

Embodiments of the present disclosure relate to a D-amino acid oxidase mutant and application in preparing L-glufosinate thereof. The D-amino acid oxidase mutant has an amino acid substitution at at least one of position 62 and position 226 of an amino acid sequence of the D-amino acid oxidase mutant when compared to an amino acid sequence of a D-amino acid oxidase as set forth in SEQ ID NO. 1, the position 62 and position 226 being defined with reference to SEQ ID NO. 1, and the amino acid sequence of the D-amino acid oxidase mutant having at least 90% identity to SEQ ID NO. 1.

The present invention relates to the technical field of biosynthesis, and in particular to a method for preparing S-nicotine. Amine oxidase is utilized to oxidize 1-methylpyrrolidine into corresponding imine, and then the imine and nicotinic acid are condensed and decarboxylated under the catalysis of nicotine synthetase to obtain a final product S-nicotine. The S-nicotine having specific chirality can be obtained by means of two-step reaction in a reaction system, the synthetic route is short, the yield is high, the reaction conditions are mild, and large-scale production is easy to achieve; moreover, raw materials are wide in source, low in price, low in production cost and environmentally friendly, the production cost of nicotine is remarkably reduced, and the requirements of current green industrial production can be better satisfied.

Agents, kits, and methods that utilize oxygenation to treat Inflammatory Bowel Disease (IBD) and/or provide prophylaxis against exacerbation of IBD are provided. In several embodiments, the agents, kits, and methods according to several embodiments generate in, or carry to, oxygen in the intestinal lumen to treat IBD and provide prophylaxis against exacerbation of IBD, including those caused by the presence of anaerobic bacteria in the intestine. The agents, kits, and methods provided herein generate an aerobic environment within the intestine to alleviate intestinal inflammation.

The present invention relates to isolated polypeptides having catalase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Composition, preferably, in the form of capsules or chewable wafers in quantities suitable for relieving the symptoms of fibromyalgia comprise formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients are described.

Modified Saccharomyces cerevisiae yeast that produce terminal alkenes are described. The modification of the Saccharomyces cerevisiae yeast includes insertion of at least one heterologous fatty acid decarboxylase gene, deletion of FAA1 and FAA4, overexpression of HEM3, and triple-deletion of CTT1, CTA1 and CCP1. Methods of producing terminal alkenes by culturing and fermenting the modified Saccharomyces cerevisiae yeast and optionally harvesting the terminal alkenes are also described. Mixtures of terminal alkenes produced by the modified Saccharomyces cerevisiae yeast, and methods of metabolically engineering a yeast for optimizing overexpression of one or more alkenes are also described.

A composition comprised of a perodixase, a catalase and a peroxide that, in combination, is suitable for degradation of pollen wall sporopollenin, and coatings comprising sporopollenin in a matrix that can be selectively degraded through application of a peroxidase, a catalase and a peroxide to the sporopollenin matrix.

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

The invention is directed to a method of treating a spinal cord injury, a neurodegenerative disease or a neuronal injury in an individual in need thereof comprising administering an effective amount of superoxide dismutase (SOD) and catalase to the individual, wherein the superoxide dismutase and the catalase are encapsulated in one or more nanoparticles that release the SOD and catalase upon administration. Another aspect of the invention is directed to compositions comprising superoxide dismutase (SOD) and catalase encapsulated in one or more nanoparticles.